GSK (NYSE:GSK) Issues FY 2025 Earnings Guidance

Key Points

• GSK updated its FY 2025 earnings guidance, projecting an earnings per share of $4.590 and revenue of $42.7 billion.
• The company's quarterly dividend has increased to $0.4216, resulting in an annualized dividend yield of 4.47%.
• Analysts have mixed ratings on GSK, with the majority giving it a hold rating, while one analyst has rated it a strong sell.

GSK (NYSE:GSK - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 4.590-4.590 for the period. The company issued revenue guidance of $42.7 billion-$42.7 billion.

GSK Price Performance

NYSE GSK traded down $1.83 during trading hours on Thursday, hitting $37.15. 8,005,575 shares of the company's stock traded hands, compared to its average volume of 5,857,341. GSK has a 52-week low of $31.72 and a 52-week high of $44.67. The company has a market capitalization of $75.83 billion, a PE ratio of 17.20, a PEG ratio of 1.59 and a beta of 0.50. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58. The firm's 50-day moving average is $38.98 and its 200-day moving average is $37.63.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 50.68%. The company had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same quarter in the prior year, the company earned $0.43 EPS. GSK's revenue was up 1.3% compared to the same quarter last year. Equities analysts forecast that GSK will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 4.5%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio is currently 79.17%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Berenberg Bank reiterated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. BNP Paribas assumed coverage on shares of GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price on the stock. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, Wall Street Zen lowered shares of GSK from a "buy" rating to a "hold" rating in a report on Saturday, July 26th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $37.38.

Hedge Funds Weigh In On GSK

Several large investors have recently made changes to their positions in GSK. Empowered Funds LLC lifted its holdings in GSK by 2.1% during the 1st quarter. Empowered Funds LLC now owns 79,174 shares of the pharmaceutical company's stock worth $3,067,000 after buying an additional 1,598 shares in the last quarter. AQR Capital Management LLC lifted its holdings in GSK by 84.4% during the 1st quarter. AQR Capital Management LLC now owns 40,239 shares of the pharmaceutical company's stock worth $1,559,000 after buying an additional 18,420 shares in the last quarter. Finally, Brighton Jones LLC acquired a new stake in shares of GSK in the 4th quarter valued at $528,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.